Late Breaking Abstract - Impact of eosinophil levels on lung function and exacerbation benefits with co-suspension delivery technology budesonide/glycopyrronium/formoterol metered dose inhaler (BGF MDI) in COPD (KRONOS study subgroup analysis)

L. Fabbri (Gothenburg, Sweden), K. Rabe (Kiel, Germany), F. Martinez (New York, United States of America), G. Ferguson (Farmington Hills, United States of America), C. Wang (Beijing, China), M. Ichinose (Sendai, Japan), E. Bourne (Durham, United States of America), S. Ballal (Morristown, United States of America), P. Darken (Morristown, United States of America), K. Deangelis (Durham, United States of America), M. Aurivillius (Mölndal, Sweden), P. Dorinsky (Durham, United States of America), C. Reisner (Morristown, United States of America)

Source: International Congress 2018 – Integrated care and non-pharmacological management of COPD
Session: Integrated care and non-pharmacological management of COPD
Session type: Thematic Poster
Number: 688
Disease area: Airway diseases

Congress or journal article abstractE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
L. Fabbri (Gothenburg, Sweden), K. Rabe (Kiel, Germany), F. Martinez (New York, United States of America), G. Ferguson (Farmington Hills, United States of America), C. Wang (Beijing, China), M. Ichinose (Sendai, Japan), E. Bourne (Durham, United States of America), S. Ballal (Morristown, United States of America), P. Darken (Morristown, United States of America), K. Deangelis (Durham, United States of America), M. Aurivillius (Mölndal, Sweden), P. Dorinsky (Durham, United States of America), C. Reisner (Morristown, United States of America). Late Breaking Abstract - Impact of eosinophil levels on lung function and exacerbation benefits with co-suspension delivery technology budesonide/glycopyrronium/formoterol metered dose inhaler (BGF MDI) in COPD (KRONOS study subgroup analysis). 688

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you: